linjc16/ctgov huggingface dataset:
Interest in Using Ultrasound Fusion in Percutaneous Interventional Radiology

Study Overview
=================
Brief Summary
-----------------
The investigators want to evaluate the accuracy of an ultrasound fusion guiding system in the positioning of a needle (here the accuracy is evaluated with a 22G spinal needle), by comparing the path indicated by the ultrasound fusion (virtual line) and the path actually obtained on the control CT scan (real line). Compared with ultrasound guidance alone or CT scan alone, the results are expected to be more accurate, saving time and irradiation (not evaluated here).

Official Title
-----------------
Interest in Using Ultrasound Fusion in Percutaneous Interventional Radiology

Conditions
-----------------
Tissular Lesion

Intervention / Treatment
-----------------
* Device: Ultrasound fusion guiding system - TUS A-500 (Aplio 500)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age>18 years male or female women of childbearing potential should use effective contraceptive measures and indicate the date of the last menstrual Patient requiring the use of computed tomographic guidance to perform a diagnostic (biopsy) or therapeutic procedure (infiltration, ablation) on a mobile organ patient signed an informed consent Exclusion Criteria: Contraindications to the use of X-rays (pregnancy) Patients using vital electronic devices (eg: pacemaker or defibrillator) Subject under judicial protection Subject under tutorship or curatorship Inability to give informed informations (subject in emergency situations, comprehension difficulties of the subject, ...)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Ultrasound fusion guiding system<br> | Device: Ultrasound fusion guiding system - TUS A-500 (Aplio 500)<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measure of the averages (m) errors of the coordinates in the three planes of space, between the virtual and the real line of the spinal needle (comparison of ultrasound fusion data with control CT scan data achieved once the spinal needle is placed) |  | time of the procedure | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| distance between the center of the target and the extension of the spinal needle (perpendicular line to this projection through the center of the lesion) |  | time of the procedure | 
| overall satisfaction score |  | time of the procedure | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Diagnostic (Biopsy) or Therapeutic Procedure (Infiltration, Ablation)
Fertility Preservation in Transgender Persons: A Retrospective Look

Study Overview
=================
Brief Summary
-----------------
Patients in this study will be asked how they feel about the decision to freeze gametes, using a validated questionnaire. In addition, a number of questions with free text fields will be included in the questionnaire to write down any reasons for their satisfaction or regret. In a second part, the intention to use the frozen material will be assessed. We focus on techniques with real perspectives (e.g. cryopreservation of oocytes and sperm cells) and not on techniques that are more experimental for later use (cryopreservation of ovarian and testicular tissue).

Official Title
-----------------
Fertility Preservation in Transgender Persons: A Retrospective Look at the Decision and a Survey of the Desire for Children.

Conditions
-----------------
Fertility Preservation in Transgender Persons

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Dutch speaking Sperm or oocyte preservation between june 2015 and june 2020. Survey in 2021 Exclusion Criteria: Ovarian and testicular tissue cryopreservation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Transgender people's retrospective view of the decision | Study of transgender persons' retrospective evaluation of the decision to freeze egg or sperm cells prior to gender-confirming hormonal or surgical treatment in transition | fertility preservation between june 2015 and june 2020 (5 years). Survey in 2021 (up to 7 years after preservation) | 
| Satisfaction/ regret about the decision | Survey on the reasons for satisfaction/ regret regarding the decision to freeze egg cells or sperm cells prior to gender-confirming hormonal or surgical treatment in the context of transition | fertility preservation between june 2015 and june 2020 (5 years). Survey in 2021 (up to 7 years after preservation) | 
| Intention | Examination of the intention to use the frozen egg cells or sperm cells to fulfil a desire to have children | fertility preservation between june 2015 and june 2020 (5 years). Survey in 2021 (up to 7 years after preservation) |
A Trial of Prostaglandin E2 Tablets Versus Foley Catheter for Labor Induction

Study Overview
=================
Brief Summary
-----------------
A randomized controlled trial comparing labor induction with vaginal PGE2 tablets and foley catheter for cervical ripening.

Official Title
-----------------
Cervical Ripening at Term With Prostaglandin E2 Tablets Versus Foley Catheter: a Randomized Controlled Trial

Conditions
-----------------
Labor, Induced

Intervention / Treatment
-----------------
* Drug: Prostin (PGE2) tablets
* Device: Foley catheter


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Singleton term pregnancies (>37 weeks), vertex presentation Intact membranes Low Bishop score (<7) First, second or third delivery Medical indication for induction Viable fetus Exclusion Criteria: Contraindication for vaginal delivery, for PGE2 or foley catheter Gestational age<37 weeks, premature rupture of membranes, fetal or uterine malformations, previous cesarean section, uncertain dating, unwilling to participate in trial

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: PGE2<br>Patients allocated to vaginal PGE2 (Prostin) for cervical ripening | Drug: Prostin (PGE2) tablets<br> <br> |
| Active Comparator: Foley catheter<br>Patients allocated to foley catheter placement for cervical ripening | Device: Foley catheter<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to active labor | Hours from foley cather placement or first PGE2 tablet placment to active labor, defined as cervical dilitation >4 cm and/or cervical effacement>80% | Post labor- up to 24 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Delivery within 24 hours | Delivery within 24 hours from foley catheter /first PGE2 tablet palcement | post-labor - up to 24 hours | 
| Cesarean section rate | Delivery via cesarean section | post labor - up to 24 hours | 
| Maternal complications | Documented complications during labor, including: excessive hemmorhage, infection (chorioamnionitis) | participants will be followed for labor course and the duration of hospital stay, an expected average of 5 days | 
| Neonatal complications | Documented complications such as non-reassuring fetal heart rate, fetal pH, NICU admission, early neonatal sepsis | Neonates of participants will be followed for labor course and the duration of hospital stay, up to 1 month |
Vagus Nerve Injury Post Radiofrequency Catheter Ablation for Atrial Fibrillation

Study Overview
=================
Brief Summary
-----------------
This study is an observational study designed to determine the extent of gastrointestinal (GI) post-procedure complications after Radiofrequency Catheter Ablation (RFCA) for atrial fibrillation (AF). This exploratory study will evaluate patient symptoms prior to the RFCA procedure, at 1 month post RFCA procedure, and at 3 months post RFCA procedure, through the administration of a questionnaire. The purpose of this study is to determine if vagus nerve injury resulting from RFCA for AF increases the risk of post-procedure GI complications that may present as temporary or permanent symptoms.

Official Title
-----------------
Vagus Nerve Injury Post Radiofrequency Catheter Ablation for Atrial Fibrillation (Vagus Nerve Study)

Conditions
-----------------
Atrial Fibrillation, Gastrointestinal Tract, Radiofrequency Catheter Ablation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with a verified medical history of atrial fibrillation. Male or female >18 years of age. Patients scheduled for an RFCA procedure, subsequent to failure of one Antiarrhythmic Drug (AAD class I, III or IV), or ablation. Ability to answer questions posed by the questionnaire. Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of any study procedures. Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Symptoms Associated with Vagus Nerve Injury | The composite of symptoms associated with vagus nerve injury: increased heart rate, bloating, early satiety, heartburn, changes in bowel habits, weight loss, problems with swallowing, nausea and vomiting. These symptoms will be discovered through the administration of a questionnaire. | At RFCA procedure, 1 month post RFCA procedure, 3 months post RFCA procedure |
Brain Imaging and Pain in Irritable Bowel Syndrome

Study Overview
=================
Brief Summary
-----------------
This study examines the mechanisms, including brain imaging of placebo analgesia

Official Title
-----------------
Brain Imaging and Pain: Analysis of Placebo Analgesia

Conditions
-----------------
Irritable Bowel Syndrome

Intervention / Treatment
-----------------
* Drug: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Irritable Bowel Syndrome English speaking Exclusion criteria: Chronic pain condition other than Irritable Bowel Syndrome Medical condition that would contraindicate use of lidocaine Clinical criteria for fibromyalgia Presence of systemic disease such as diabetes, thyroid, gastrointestinal or liver disease, collagen vascular disease, malignancy, focal or neurological Seropositive HIV Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: placebo|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Placebo, Analgesia, Pain, Brain mechanism, Expectation
Effect of Ischemic Compression With Stretching on Patients With Upper Back Pain

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the effect of ischemic compression with stretching on pain related parameters including pain intensity, pressure pain threshold, anxiety, cervical range of motion and patient satisfaction in patients with scapular pain associated with myofascial trigger point.

Official Title
-----------------
Effect of Ischemic Compression With Stretching on Pain Related Parameters in Patients With Upper Back Pain Associated With Myofascial Trigger Point

Conditions
-----------------
Myofascial Pain Syndrome

Intervention / Treatment
-----------------
* Other: Ischemic compression with stretching


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The participants have experienced spontaneous upper back pain for longer than 12 weeks (chronic) and that at least one trigger point will be present in the s trapezius muscles. Trigger points will be diagnosed as the presence of focal tenderness in a taut band and with pain recognition. The participants will be able to follow instructions. Good communication and cooperation. Exclusion Criteria: Fibromyalgia syndrome Cervical radiculopathy or myelopathy) Cervical spine surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Ischemic compression with stretching<br>The participants will receive the ischemic compression with stretching onto the trapezius muscle | Other: Ischemic compression with stretching<br> <br> |
| No Intervention: Control<br>Rest on the bed | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain score on Visual analog scale | The intensity of pain will be reported by the participant on a visual analog scale ranging from 0 to 10. Zero indicates no pain anywhere and 10 indicates the most pain ever experienced | 5 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pressure Pain Threshold as a measure by pressure algometry |  | 5 weeks | 
| Anxiety on State Anxiety Inventory |  | 5 weeks | 
| Cervical range of motion |  | 5 weeks | 
| Patient satisfaction level |  | 5 weeks |
A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients With Metastatic Breast Cancer.

Study Overview
=================
Brief Summary
-----------------
This is a study to explore how well the combination of LY231514 and Gemcitabine work together in patients with breast cancer that has spread beyond the location of the original tumor. Patients must have previously received treatment with anthracycline and taxane chemotherapy drugs.

Detailed Description
-----------------
Gemcitabine is given by vein over 30 minutes on days 1 & 8 of each 21-day cycle. LY231514 is also given by vein over 10 minutes on day 8, following the Gemcitabine injection. Vitamin supplementation with oral folic acid and injectable B12 is initiated 7-10 days prior to the first dose of LY231514, and continuing throughout the patient's participation. Vitamin B12 is administered approximately every 9 weeks after the first injection. Appropriate antiemetic medication should be given to all patients. Dexamethasone 4mg PO twice daily is given for 3 days per cycle, beginning 1 day prior to LY231514 dosing. This is given to prevent or lessen the possibility of a rash.

Official Title
-----------------
A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients With Metastatic Breast Cancer.

Conditions
-----------------
Breast Neoplasms

Intervention / Treatment
-----------------
* Drug: pemetrexed
* Drug: gemcitabine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: confirmed diagnosis of breast cancer measurable disease received prior anthracycline and taxane life expectancy > 3 months acceptable lab results Exclusion Criteria: >3 prior regimens prior treatment with protocol drugs prior (pelvic) radiation active CNS metastasis inability to take oral vitamins

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: pemetrexed|nan|
|Drug: gemcitabine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Alimta, metastatic breast cancer, combination therapy
HIV and Inflammatory or Autoimmune Disease: Rare Patients, Many Questions (MAIVIH)

Study Overview
=================
Brief Summary
-----------------
Follow-up registry of patients living with HIV who also have various inflammatory and autoimmune pathologies that may require immunosuppressive treatment.

Official Title
-----------------
HIV and Inflammatory or Autoimmune Disease: Rare Patients, Many Questions (MAIVIH)

Conditions
-----------------
Hiv

Intervention / Treatment
-----------------
* Other: data collection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient living with HIV Carrier of one or more of the following diseases: Sarcoidosis Multiple sclerosis Myasthenia gravis Crohn's disease Hemorrhagic rectocolitis Autoimmune hepatitis Arthropathic psoriasis Still's disease, other rheumatoid arthritides, juvenile polyarthritides, Rheumatoid arthritis Vasculitides: periarteritis nodosa and related conditions, other necrotizing vasculopathies (periarteritis nodosa, juvenile periarteritis, Churg-Strauss disease, polyangiitis, Kawasaki disease, Horton's disease, Wegener's disease, thrombotic microangiopathy, Takayashu syndrome, Good-Pasture's syndrome, thrombocytopenic purpura) Lupus Polymyositis or dermatopolymyositis Connectivitis (Behcet's disease, Gougerot-Sjöogren syndrome) Inflammatory spondyloarthropathies (APS, spondyloarthritis, other spondyloarthropathies) Exclusion Criteria: Opposition of the person Minor patients Patients under judicial protection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: data collection|data collection|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients living with HIV who have an inflammatory or autoimmune disease |  | At the end of the study an average of 18 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients on immunosuppressive treatment, |  | At the end of the study an average of 18 months | 
| Occurrence of infectious complications |  | At the end of the study an average of 18 months | 
| Number of patients on remission |  | At the end of the study an average of 18 months | 
| Evolution of CD4 and HIV viral load |  | At the end of the study an average of 18 months |
Kidney Damage in Patients With Normal eGFR

Study Overview
=================
Brief Summary
-----------------
This is a pilot study, randomized, double-blind, parallel group comparison of two iodinated contrast agents used during percutaneous coronary intervention (PCI). All patients enrolled must have normal eGFR. Statistical summaries will be presented to analyse the various laboratory tests for the two groups.

Official Title
-----------------
A Phase IV Pilot Study to Evaluate Kidney Damage Measured by Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a New Bio-Marker in Patients With Normal eGFR Undergoing Percutaneous Coronary Intervention With IOPAMIDOL Injection 370 or IODIXANOL 320

Conditions
-----------------
Coronary Artery Stenosis

Intervention / Treatment
-----------------
* Drug: Non ionic contrast media comparator
* Drug: Non ionic contrast media comparator


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Provides written Informed Consent and is willing to comply with protocol requirements; Is at least 18 years of age; Is scheduled to undergo a percutaneous coronary intervention and/or diagnostic coronary angiography. Has documented estimated glomerular filtration rate [eGFR] ≥60 mL/min/1.73 m2 calculated with the MDRD formula within 72 hours prior to enrollment. Exclusion Criteria: Is a pregnant or lactating female. Has a history of severe congestive heart failure Has a history of hyperthyroidism Has a history of hypersensitivity to iodinated contrast agents Has unstable renal function

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: IOPAMIDOL 370<br> | Drug: Non ionic contrast media comparator<br>* One time administration for PCI<br>* Other names: Isovue 370;|
| Active Comparator: IODIXANOL 320<br> | Drug: Non ionic contrast media comparator<br>* one time administration for PCI<br>* Other names: Visipaque 320;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Impact on the Trajectory of Serum and Urinary NGAL Following the Administration of Non-ionic Low Osmolar Contrast Media. | Mean change from baseline values for serum NGAL at 2,4,6,24,48 and 72 hours, and urine NGAL at 2,4,6,24, and 48 hours following the administration of non-ionic low osmolar contrast media. | Baseline and 2, 4, 6, 24, 48, and 72 hours post-dose |